Annovis Bio: Latest News, Top Stories & Analysis

Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients

October 13, 2025October 12, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …

Executives

Annovis Bio Names Mark Guerin CFO as Buntanetap Nears Late-Stage Milestones

September 29, 2025September 29, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer, bringing on a seasoned financial leader to guide the company through …

Research

Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug

September 28, 2025September 27, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its …

Research

Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate

September 20, 2025September 19, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has published new research in the journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, its lead drug …

Public Companies

Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference

September 6, 2025September 5, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that Chief Executive Officer Maria Maccecchini, Ph.D., will deliver a presentation at the H.C. Wainwright 27th Annual Global Investment Conference in …

Public Companies

Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio

August 15, 2025August 14, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported progress on its pivotal Phase 3 trial in early Alzheimer’s disease while posting improved second-quarter financial results and expanding its intellectual …

Products and Services

Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap

August 9, 2025August 7, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the successful transfer and rewrite of all its intellectual property protections to cover a newly developed crystalline form of its lead drug …

Public Companies

Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference

June 26, 2025June 26, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has announced its participation in the prestigious Alzheimer’s Association International Conference (AAIC) 2025. The global event, set to take place from July …

Public Companies

Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards

June 19, 2025June 19, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced it has received an “Acceptance Letter” from the New York Stock Exchange (NYSE), confirming the NYSE’s approval of the Company’s plan …

Business

Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development

June 6, 2025June 5, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a live webcast with Maria Maccecchini, Ph.D., President and CEO, to provide updates and answer audience questions.